Loading...

Revenio Group Oyj

0KFH.L•LSE
Healthcare
Medical - Equipment & Services
£28.00
£0.00(0.00%)

Revenio Group Oyj (0KFH.L) Stock Overview

Explore Revenio Group Oyj’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 75.3/100

Key Financials

Market Cap737.1M
P/E Ratio39.20
EPS (TTM)$0.69
ROE0.18%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 Month$27.19
3 Months$32.39
1 Year Target$28.84

0KFH.L Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Revenio Group Oyj (0KFH.L) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 63.67, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $28.84.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 39.20 and a market capitalization of 737.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

63.67RSI (14)
1.23MACD
46.30ADX
Revenue Growth
7.17%
↑ 7.17%
Profit Growth
£0.72
↓ 3.19%
EPS Growth
£0.72
↓ 4.17%
Operating Margin
25.02%
↓ 5.10%
ROE
18.25%
↓ 3.19%
Dividend Yield
0.00%
↑ 5.32%
Analyst Recommendations data is not available for 0KFH.LAnalyst Recommendations details for 0KFH.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Revenio Group Oyj, a health technology company, designs, manufactures, and sells ophthalmic diagnostics and devices for the detection of glaucoma, macular degeneration, diabetic retinopathy, and cataracts in Finland, rest of Europe, and internationally. The company offers iCare IC100 and IC200 tonometers; iCare HOME, a device for self-measurement of eye pressure; imaging devices comprising iCare EIDON AF, a device with confocal retinal imaging; DRSplus, a device for detection of diabetic retinopathy; iCare MAIA, a microperimeter to measure the visual field; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images. It also provides Oculo, an eye care software platform, which combines clinical communication, telehealth, remote patient monitoring and data analytics capabilities. Revenio Group Oyj was incorporated in 2001 and is based in Vantaa, Finland.

CEO

Jouni Toijala

Employees

246

Headquarters

Äyritie 22, Vantaa

Founded

2015

Frequently Asked Questions

;